Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?

Impact · against what's priced in

The stock is effectively capped by the pending acquisition by Merck KGaA at $73 per share. Near-term earnings expectations for Q1 fiscal 2027 are already reflected in the consensus, providing no immediate catalyst for the price to move beyond the deal terms.

TECH+0.00

No priced-in read yet

In context

The stock is governed by the definitive agreement for Merck KGaA to acquire the company for $73 per share in cash. Quarterly revenue and EPS estimates for Q1 fiscal 2027 are standard expectations and do not alter the acquisition valuation.

Read from the article alone

• earnings▲2%
• healthcare
• guidance
• m and a
• biotech
• TECH
• diagnostics
• life sciences

Top 1 mover · tap to explore